Executive Leadership Team

John Timberlake , President & Chief Executive Officer

John Timberlake has served as our chief executive officer, president and chief commercial officer and a member of our board of directors since February 2016, prior to which he served as president and chief commercial officer since August 2008. Before becoming chief executive officer, president and chief commercial officer, Mr. Timberlake was a general manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis (now Sanofi), with his last role as vice president of diabetes marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. While at Sanofi, Mr. Timberlake had extensive experience and commercial responsibilities for new products in development across multiple therapeutic areas, including inhaled insulin and other metabolic products. Prior to working in the healthcare industry, Mr. Timberlake was a manager with Deloitte & Touche LLP from 1986 to 1991 and was both a certified management accountant and a certified public accountant. He earned a B.S. in Accounting at Northwest Missouri State University, an M.S. in management from Purdue University and an MBA from ESC Rouen in France (now NEOMA Business School).

Geoffrey Jenkins , Executive Vice President, Manufacturing, Operations, and R&D

Geoffrey Jenkins has served as our executive vice president, manufacturing, operations and research & development since he joined Valeritas in April 2009. Prior to joining Valeritas, Mr. Jenkins was vice president of worldwide operations for Inverness Medical Innovations, a healthcare technology company, from 2005 to 2009. From 2000 to 2005, he was president and founding partner of UV-Solutions, LLC, a healthcare technology company, and from 1997 to 1999, he was chief operating officer of MDI Instruments, Inc., a healthcare technology company. Mr. Jenkins was also corporate vice president of operations of MediSense, Inc. from 1991 to 1997. Prior to becoming corporate vice president of operations, he held various other positions in operations and engineering management with MediSense from 1984 to 1991. Mr. Jenkins earned a Bachelor of Arts and a Bachelor of Science from Clarkson University.

Erick Lucera , Executive Vice President & Chief Financial Officer

Erick Lucera joined the company as Chief Financial Officer in August 2016. Prior to joining Valeritas, Mr. Lucera served as Chief Financial Officer, Treasurer and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company’s product pipeline through a series of acquisitions and in licensing transactions financed through 5 public and private offerings of nearly $250 million. In 2012, he served as Vice President, Corporate Development at Sunshine Heart, a medical device manufacturer. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence Investments. He holds a CPH from Harvard University, and MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.

Matthew Nguyen , PharmD , Chief Commercial Officer

Matthew Nguyen has served as senior vice president, commercial since February 2016, prior to which he served as vice president for integrated healthcare management since joining Valeritas in September 2006. Prior to joining Valeritas, Mr. Nguyen was a new business development director for Janssen, LP, a division of Johnson & Johnson, from 2005 to 2006. Prior to joining Janssen, LP, he served as head of health economics research for metabolism, new product marketing and head of analytics and commercial effectiveness for the CNS business unit at Sanofi from 2000 to 2005. Mr. Nguyen earned a Bachelor of Science in pharmacy and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He also completed a fellowship in health economics and outcomes research in conjunction with Thomas Jefferson University Hospital and Janssen Pharmaceuticals, Inc. and earned an MBA from Rutgers University.

Joseph Saldanha , Chief Business Officer

Joseph Saldanha joined Valeritas in January 2018. He has over 15 years of diabetes experience and over 25 years in the industry. In roles prior to joining Valeritas, Mr. Saldanha spent several years at Sanofi and its predecessors, launching Actonel for osteoporosis in the US, and for Lantus in international markets from Paris. He worked in Business Development at Johnson and Johnson Diabetes (LifeScan for self-monitoring blood glucose and Animas for insulin pumps). Mr. Saldanha has also worked in the United Arab Emirates in a General Management role with responsibility for inulin API, diabetes orals and injectables, and distribution of Dexcom CGM for the Middle-Eastern markets. He has worked on the Aventis-Pfizer partnership for Exubera and in commercial and Business Development roles for MannKind. Mr. Saldanha earned a Bachelor of Science degree from Drexel University and a Master of Science degree from the University of Pennsylvania, both in Philadelphia.

Senior Management Team

Scott Huie , Vice President, Regulatory Affairs/Quality Assurance and Compliance

Scott Huie joined Valeritas in 2002. He has over 30 years’ experience in medical device, pharmaceutical and combination products and has held roles in product/process development, operations, regulatory and quality. Scott was previously vice president, operations at Fusion Medical Technologies, which was acquired by Baxter Healthcare Corporation. He has also worked at Aradigm, Cygnus Therapeutic Systems, Ciba-Geigy and 3M Company. Scott received his Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute.

Chris Gregory , Ph.D. , Vice President, Research and Development

Chris Gregory joined Valeritas in March 2013 as vice president of research and development. He has been developing disposable and durable medical devices since 1986. Prior to joining Valeritas, Chris was director of U.S. research and development for ConvaTec Inc., a disposable medical device company that was originally a division of Bristol-Myers Squibb. At ConvaTec, he was responsible for R&D and maintenance for product lines worth $700 million in annual revenue. Before ConvaTec, Chris was group head for medical devices at Sarnoff Corporation, formally the R&D center for RCA Corp. He also held engineering positions in medical device development at Galileo Electro-Optics and Heraeus LaserSonics. Chris earned a Bachelor of Science and Master of Science from Brown University and a Ph.D. in engineering from Rutgers University.

Jeffrey Zajac , Vice President, Operations

Mr. Zajac was promoted to Vice President, Operations in January 2018 after serving as Sr. Director - Operations, Sr. Director – Program Management and Director Operations Program Management since joining Valeritas in 2013. Mr. Zajac brings more than 20 years of manufacturing and operations management experience in medical devices and contract manufacturing to Valeritas. Prior to joining Valeritas, Mr. Zajac spent 4 years with Jabil, a leading manufacturing service provider to the healthcare & life science businesses as a Global Technical Director – Healthcare & Life Sciences,; and 6 years as a Technical Director for Accellent, Inc. a contract design and manufacturing organization focused on the medical marketplace. Mr. Zajac earned a Bachelor of Engineering, degree from Stevens Institute of Technology and an MBA from the University of Rhode Island.

Mark Conley , Vice President, Corporate Controller and Treasurer

Mark Conley has served as vice president, corporate controller and treasurer since February 2016, prior to which he served as our director of financial planning & analysis since joining Valeritas in August 2012. Prior to joining Valeritas, Mark was global finance director of the radiation instrumentation business at Thermo Fisher Scientific from 2007 to 2012. In addition, he served at Iron Mountain, Inc. as vice president, financial planning & analysis from 2005 to 2007 and division controller from 1998 to 2004; as chief financial officer & controller at HoltraChem Group from 1996 to 1998; and in successive financial leadership roles, including operations controller at Haemonetics Corporation from 1991 to 1996. Mr. Conley earned a Bachelor of Science in accounting from Oklahoma State University and an MBA from Bryant College and is a certified public accountant.

Hokan Lars Ojert , Vice President, Sales

Hokan Lars Ojert joined Valeritas in January 2007. Hokan has over 18 years of diabetes sales and marketing experience, most recently with Sanofi and its predecessor companies. During his time at Sanofi, Hokan held numerous leadership positions within sales and marketing. His career has afforded him the experience of launching, selling and marketing products such as Amaryl®, Apidra®, Lantus®, and the OptiClik® and SoloSTAR® pen technologies. He was the U.S. marketing lead on the commercialization of the OptiClik® pen and involved with the pre-market development of the SoloSTAR® pen technology. Along with Hokan's vast sales and marketing experience within the diabetes arena, he also brings significant recruiting and hiring capabilities to our organization. Hokan led a sales-force scale-up initiative within the diabetes sales division in the Southeast United States. Hokan is a graduate of the University of Scranton, where he earned a Bachelor of Science degree in management.

Dave Lewis , Vice President, Marketing

David Lewis joined Valeritas in June 2016. Mr. Lewis brings with him more than 20 years of healthcare industry marketing experience having led product launch teams for both Merck and Bristol-Myers Squibb/AstraZeneca. Mr. Lewis has extensive experience in the diabetes market having served as Senior Director and Team Lead for Merck’s launch of Januvia® followed by his leadership over the global launch of Forxiga® during his tenure with AstraZeneca and Bristol-Myers Squibb as Executive Director of Marketing. Mr. Lewis has also led the development and execution of commercial strategies and plans for several smaller startup bio-pharma companies. Mr. Lewis holds a bachelor of science degree in engineering from Michigan State University and earned his MBA from Purdue University’s Krannert School of Management.

Kyle Treude , Vice President Managed Care

Kyle Treude joined Valeritas in July 2017. Mr. Treude is an accomplished Sales and Market Access leader with over 20 years of sales, sales management and reimbursement channel leadership experience in high growth diabetes device organizations. In 2006, Mr. Treude joined Dexcom in a sales leadership capacity to oversee the first commercial launch of Dexcom’s CGM technology in the US market. He was later promoted in 2010 to develop and execute Dexcom’s Market Access strategies nationally to drive payer adoption of CGM, as well as the development of their distribution channel. Prior to his tenure with Dexcom, he spent six years with Medtronic MiniMed developing and growing the insulin pump and CGM markets. Mr. Treude holds a bachelor of science degree in Biological Sciences from the University of California Santa Barbara and earned his MBA from Arizona State University’s W.P. Carey School of Management.